Q-omics provides the consensus-scored RPSAP69 profile across patient tissues and cancer cell-line models. RPSAP69 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPSAP69 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, RPSAP69 RNA expression shows 14,426 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUSC, and GBM as cancer lineages where RPSAP69 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP69 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP69 survival associations across molecular data types. RPSAP69 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP69 RNA expression–survival associations across cancer types. High RPSAP69 expression shows unfavorable associations in KIRC, KICH, UCEC, PRAD and ACC, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPSAP69 RNA expression.
This table summarizes RPSAP69 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP69. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP69 shows higher tumor expression in LUSC, COAD, UCEC, BLCA, LUAD and THCA. The LUSC box plot shows higher RPSAP69 RNA expression in tumor versus normal tissue (log2 FC = +1.182, t-test p < 0.001).
This table shows molecular features associated with RPSAP69 in patient tissues and cancer cell lines. In patient samples, RPSAP69 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
